Goldman Sachs’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-209,298
| Closed | -$333K | – | 6053 |
|
|
2024
Q1 | $333K | Buy |
209,298
+98,616
| +89% | +$146K | ﹤0.01% | 4924 |
|
|
2023
Q4 | $95.1K | Sell |
110,682
-162,679
| -60% | -$143K | ﹤0.01% | 5301 |
|
|
2023
Q3 | $292K | Buy |
273,361
+36,625
| +15% | +$75.8K | ﹤0.01% | 4900 |
|
|
2023
Q2 | $613K | Buy |
236,736
+45,933
| +24% | +$164K | ﹤0.01% | 4628 |
|
|
2023
Q1 | $778K | Sell |
190,803
-188,855
| -50% | -$873K | ﹤0.01% | 4565 |
|
|
2022
Q4 | $1.91M | Buy |
379,658
+46,019
| +14% | +$288K | ﹤0.01% | 3987 |
|
|
2022
Q3 | $4.36M | Buy |
333,639
+161,433
| +94% | +$2.44M | ﹤0.01% | 3247 |
|
|
2022
Q2 | $2.21M | Buy |
172,206
+8,288
| +5% | +$115K | ﹤0.01% | 3953 |
|
|
2022
Q1 | $2.5M | Sell |
163,918
-42,896
| -21% | -$669K | ﹤0.01% | 4045 |
|
|
2021
Q4 | $3.66M | Sell |
206,814
-44,671
| -18% | -$857K | ﹤0.01% | 3719 |
|
|
2021
Q3 | $5.29M | Buy |
251,485
+193,662
| +335% | +$4.26M | ﹤0.01% | 3313 |
|
|
2021
Q2 | $1.14M | Buy |
57,823
+6,442
| +13% | +$151K | ﹤0.01% | 4664 |
|
|
2021
Q1 | $1.49M | Buy |
51,381
+3,356
| +7% | +$94K | ﹤0.01% | 4275 |
|
|
2020
Q4 | $1.45M | Sell |
48,025
-5,097
| -10% | -$112K | ﹤0.01% | 3952 |
|
|
2020
Q3 | $845K | Sell |
53,122
-7,274
| -12% | -$133K | ﹤0.01% | 4187 |
|
|
2020
Q2 | $1.19M | Buy |
60,396
+15,863
| +36% | +$303K | ﹤0.01% | 3836 |
|
|
2020
Q1 | $549K | Sell |
44,533
-41,986
| -49% | -$685K | ﹤0.01% | 4157 |
|
|
2019
Q4 | $1.6M | Buy |
86,519
+32,007
| +59% | +$468K | ﹤0.01% | 3795 |
|
|
2019
Q3 | $755K | Sell |
54,512
-1,691
| -3% | -$25.4K | ﹤0.01% | 4209 |
|
|
2019
Q2 | $823K | Buy |
+56,203
| New | +$823K | ﹤0.01% | 4114 |
|
Goldman Sachs's NGM Position: Q2 2024 in Review
Goldman Sachs sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 209,298 shares — an estimated $333K sold.
Goldman Sachs first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $5.29M in Q3 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Goldman Sachs reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Goldman Sachs sold 209,298 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $333K.
- Goldman Sachs first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Goldman Sachs's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $5.29M in Q3 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.